Latest Pharmaceuticals News

Page 11 of 72
Amplia Therapeutics reports a remarkable 7.8% complete response rate and improved survival in its ACCENT pancreatic cancer trial, positioning narmafotinib as a promising new treatment option.
Ada Torres
Ada Torres
23 Mar 2026
EBOS Group Limited has updated its interim dividend details for the six months ending December 2025, confirming a fully franked ordinary dividend and a supplementary dividend, alongside a Dividend Reinvestment Plan offering a 2% discount.
Ada Torres
Ada Torres
20 Mar 2026
EVE Health Group has announced a $1.3 million capital raising through a placement of shares and free attaching options, aimed at advancing its pharmaceutical product rollout and development pipeline. Several components of the offer await shareholder approval at an upcoming general meeting.
Ada Torres
Ada Torres
20 Mar 2026
AdAlta Limited has been granted a key Canadian patent for its anti-fibrotic drug AD-214, completing its composition of matter protection across all major commercial markets. This milestone strengthens the company’s intellectual property portfolio and underpins its commercial strategy for AD-214.
Ada Torres
Ada Torres
20 Mar 2026
CLINUVEL Pharmaceuticals reports record first-half profits and confirms CEO Philippe Wolgen’s leadership through a pivotal growth phase, prioritising its vitiligo program and Nasdaq ambitions.
Victor Sage
Victor Sage
20 Mar 2026
Recce Pharmaceuticals is progressing its Phase 3 clinical trial of RECCE 327, a novel synthetic antibiotic targeting multidrug-resistant infections, with interim data from Indonesia supporting registration plans across ASEAN by 2026.
Ada Torres
Ada Torres
19 Mar 2026
EVE Health Group has increased its placement funding to $1.3 million, backed by a cornerstone investor with pharmaceutical expertise, advancing its reformulated drug programs targeting billion-dollar global markets.
Ada Torres
Ada Torres
18 Mar 2026
EBOS Group Limited has updated its interim dividend announcement, specifying the Dividend Reinvestment Plan strike price and confirming payment details for the six-month period ending December 2025.
Ada Torres
Ada Torres
18 Mar 2026
Biotron Limited reveals that its lead antiviral candidate BIT-HBV001 shows promising activity against Hepatitis Delta Virus, expanding its potential impact beyond Hepatitis B. Meanwhile, the company completes integration of Sedarex and advances regulatory plans for its anaesthetic SedRx.
Ada Torres
Ada Torres
18 Mar 2026
dorsaVi has secured significant commercial and clinical milestones with new elite sports and European clinical partnerships, showcasing its advanced real-time AI sensor technology.
Victor Sage
Victor Sage
17 Mar 2026
Clarity Pharmaceuticals has unveiled compelling Phase II trial results showing its Cu-SAR-bisPSMA PET imaging agent significantly improves detection of prostate cancer recurrence over the current standard. The data, presented at the 2026 European Association of Urology Congress and accepted by European Urology journal, mark a key milestone ahead of regulatory submissions.
Ada Torres
Ada Torres
17 Mar 2026
Vitura Health has inked a binding distribution agreement with MedReleaf Australia, unlocking access to a broad medicinal cannabis portfolio across its extensive pharmacy network. This deal could add up to AUD 15 million annually, positioning Vitura as a dominant player in the evolving Australian market.
Ada Torres
Ada Torres
17 Mar 2026